Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma

Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Patients

NCT06154668 ·Status: RECRUITING

Predictive Factors of Complete Response to Immunotherapy in Metastatic Melanoma: a Single-center Retrospective Study Between 2013 and 2021

NCT07302607 ·Status: RECRUITING

DNA Repair Inhibitor & Irradiation on Melanoma

NCT01469455 ·Status: COMPLETED ·Phase: PHASE1

Immune Profiles Evolution Under Immunotherapy for Melanoma

NCT04576429 ·Status: RECRUITING ·Phase: NA

Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma

NCT04165967 ·Status: COMPLETED ·Phase: PHASE1

Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma

NCT02535078 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types

NCT06075524 ·Status: RECRUITING

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

NCT06599619 ·Status: RECRUITING

A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma

NCT01864538 ·Status: TERMINATED ·Phase: PHASE2

Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab

NCT02600169 ·Status: COMPLETED

T-cell Based Immunotherapy for of Melanoma

NCT00937625 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

NCT04695977 ·Status: TERMINATED ·Phase: PHASE2/PHASE3

Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions

NCT00091689 ·Status: COMPLETED ·Phase: PHASE1

Symptoms of Immune Checkpoint Inhibitor Therapy in Cutaneous Melanoma

NCT07148245 ·Status: RECRUITING

A Pilot Study of Ipilumimab and Radiation in Poor Prognosis Melanoma

NCT01996202 ·Status: COMPLETED ·Phase: PHASE1

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma

NCT05002569 ·Status: TERMINATED ·Phase: PHASE3

A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma

NCT04625205 ·Status: TERMINATED ·Phase: PHASE1

Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors

NCT04990726 ·Status: ACTIVE_NOT_RECRUITING

Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic Melanoma

NCT00314106 ·Status: COMPLETED ·Phase: PHASE2

A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection

NCT05297565 ·Status: COMPLETED ·Phase: PHASE3

Quality of Life and Physical Fitness After Immune Checkpoint Inhibitors

NCT03946007 ·Status: COMPLETED

An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma

NCT01137006 ·Status: COMPLETED ·Phase: PHASE1

CCI-779 in Treating Patients With Metastatic Melanoma

NCT00022464 ·Status: COMPLETED ·Phase: PHASE2

IL2 Imaging in Metastatic Melanoma

NCT02922283 ·Status: TERMINATED ·Phase: NA

A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma

NCT06594991 ·Status: RECRUITING ·Phase: PHASE2